Alphatec Holdings, Inc. (ATEC) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Alphatec Holdings, Inc. is a medical technology company focused on the design and development of technology for the surgical treatment of spinal disorders. The company operates through subsidiaries including Alphatec Spine, SafeOp Surgical, and EOS imaging. It markets products globally via independent sales agents and direct representatives.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $150.7M | $118.3M | $434.8M | $344.3M |
| Gross Profit | $102.7M | $80.0M | $302.7M | $215.0M |
| Gross Margin | 68.1% | 67.7% | 69.6% | 62.4% |
| Operating Loss | $(33.7M) | $(38.4M) | $(112.4M) | $(128.6M) |
| Net Loss | $(39.6M) | $(42.7M) | $(128.8M) | $(137.6M) |
| Cash & Equivalents | $81.0M | $122.5M | $81.0M | $122.5M |
| Total Debt (Long-term + Current) | $527.7M | $512.8M | $527.7M | $512.8M |
Note: Debt figures include $150.0M Braidwell Term Loan, $63.2M Revolving Credit Facility, and $316.3M Convertible Notes.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 27% year-over-year (YoY) in Q3 and 26% for the nine-month period, driven by increased product volume, surgeon user base expansion, and new product adoption.
- Expense Increases:
- SG&A: Increased 19% in Q3 and 24% for 9M due to higher compensation costs and investments in sales/marketing headcount.
- R&D: Increased 20% for 9M due to stock-based compensation and personnel expansion for new products.
- Interest Expense: Increased 47% in Q3 and 45% for 9M due to higher interest rates and the full draw of the Braidwell Term Loan.
- Inventory Build: Inventory levels rose to $183.1M (from $136.8M at year-end 2023), contributing to a $57.0M cash outflow in operating activities for the nine months.
- Liquidity: Cash and cash equivalents decreased by $140.0M during the nine months ended September 30, 2024, primarily due to operating losses and significant capital expenditures ($81.2M) for surgical instruments.
Outlook, Risks, and Contingencies
- Debt Amendments: On October 29, 2024, the company amended its Braidwell Term Loan to provide for an additional $50.0 million term loan.
- Warrant Obligation: A Delaware Chancery Court order requires the company to offer a warrant to purchase up to 1.13 million shares to stockholder L-5 Healthcare Partners, LLC, by November 4, 2024.
- Legal Proceedings: The company is involved in various legal proceedings, including a lawsuit filed by NuVasive, Inc. against the company and its CEO. Management does not believe any single matter will have a material adverse impact, though outcomes are unpredictable.
- Commitments: The company has a remaining minimum purchase commitment of $8.9 million with a third-party supplier through December 2026.
- Forward-Looking Risks: Risks include the ability to achieve profitability, access to capital markets, regulatory compliance, and foreign currency exchange exposure as international business grows.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the current cash position ($81M) given the $140M cash decrease in the first nine months and ongoing operating losses.
- Debt Covenants: Confirm continued compliance with liquidity covenants on the Braidwell Term Loan and Revolving Credit Facility, especially given the recent cash drawdown.
- Inventory Valuation: Assess the risk of obsolescence given the significant increase in inventory levels ($46M increase YoY) and the $11.0M write-down recorded in the nine months.
- Convertible Notes: Monitor the stock price relative to the conversion price ($18.34) and the potential for dilution or cash redemption of the $316.3M 2026 Notes.
- Warrant Issuance: Track the outcome of the court-ordered warrant offer to L-5 Healthcare Partners and its potential impact on capital structure.